
|Articles|July 9, 2015
- Gastrointestinal Cancers (Issue 5)
- Volume 4
- Issue 2
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
Author(s)Axel Grothey, MD
Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.
Articles in this issue
almost 11 years ago
Prevention and Screening of CRCalmost 11 years ago
Survival Differences in KRAS/BRAF Mutations in mCRCalmost 11 years ago
New Agents Show Potency for Patients with HCCalmost 11 years ago
Success of Regorafenib Confirmed in Patients With mCRCalmost 11 years ago
Agents Under Examination Demonstrate Success in Gastric Cancer






























